The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created
new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel …

Complicated intra-abdominal infections (cIAIs) are a common cause of morbidity and
mortality in surgical patients. Optimal management of cIAI requires early source control in …

Complicated intra-abdominal infections (cIAIs) are an important cause of morbidity and
mortality worldwide. They are diagnosed when the initial abdominal organ infection has …

Introduction: Complicated intraabdominal infections (cIAIs) are a common cause of infection-
related morbidity and mortality in hospitalized patients and present many challenges unique …

Complicated intra-abdominal infections (cIAI) represent a large proportion of all hospital
admissions and are a major cause of morbidity and mortality in the intensive care unit …

Background Carbapenem-sparing antibiotics are needed urgently for patients with
complicated intra-abdominal infections (cIAIs). Although several novel antibiotics–novel β …

Background. Increasing antimicrobial resistance among pathogens causing complicated
intra-abdominal infections (cIAIs) supports the development of new antimicrobials …

Background Increasing antimicrobial resistance among pathogens that cause complicated
intraabdominal infections (cIAIs) supports the development of new antimicrobials …

Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core
scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in …

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a
novel fluorocycline with broad spectrum of activity against resistant Gram-negative …